Is LXRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LXRX. It does not provide personalized investment advice.

LXRX (Lexicon Pharmaceuticals, Inc.) Stock Analysis - Financials

Lexicon Pharmaceuticals, Inc. (LXRX) is a publicly traded Healthcare sector company. As of October 21, 2026, LXRX trades at $1.60 with a market cap of $689.68M and a P/E ratio of -10.66. LXRX moved +0.63% today. Year to date, LXRX is +38.60%; over the trailing twelve months it is +3.95%. Its 52-week range spans $0.28 to $2.68. Analyst consensus is strong buy with an average price target of $5.78. Rallies surfaces LXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are LXRX's key financials?

LXRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LXRX recently traded at $1.60. Market cap is $689.68M. P/E ratio is -10.66. Revenue is $41.47M.

LXRX Key Metrics

Key financial metrics for LXRX
Metric	Value
Price	$1.60
Market Cap	$689.68M
P/E Ratio	-10.66
EPS	$-0.16
Dividend Yield	0.00%
52-Week High	$2.68
52-Week Low	$0.28
Volume	304.32K
Avg Volume	0
Revenue (TTM)	$41.47M
Net Income	$-61.12M
Gross Margin	99.14%

LXRX Analyst Consensus

4 analysts cover LXRX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.78.

Common questions about LXRX

What are LXRX's key financials?: LXRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LXRX recently traded at $1.60. Market cap is $689.68M. P/E ratio is -10.66. Revenue is $41.47M.
Is LXRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LXRX. It does not provide personalized investment advice.